Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Investments (2016 - 2025)

Enanta Pharmaceuticals' Long-Term Investments history spans 14 years, with the latest figure at $56.1 million for Q4 2025.

  • For Q4 2025, Long-Term Investments changed N/A year-over-year to $56.1 million; the TTM value through Dec 2025 reached $56.1 million, changed N/A, while the annual FY2022 figure was $29.3 million, 72.99% down from the prior year.
  • Long-Term Investments reached $56.1 million in Q4 2025 per ENTA's latest filing, up from $42.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $115.7 million in Q2 2021 to a low of $5.9 million in Q2 2023.
  • Average Long-Term Investments over 5 years is $49.6 million, with a median of $40.8 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: crashed 84.97% in 2023, then soared 617.59% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $88.7 million in 2021, then plummeted by 69.62% to $26.9 million in 2022, then crashed by 78.01% to $5.9 million in 2023, then skyrocketed by 617.59% to $42.5 million in 2024, then soared by 31.86% to $56.1 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Long-Term Investments are $56.1 million (Q4 2025), $42.5 million (Q2 2024), and $5.9 million (Q2 2023).